Management of serious infections caused by metallo β-lactamases with or without OXA-48-like expressing Enterobacterales with aztreonam and ceftazidime/avibactam combination: Dosing strategy for better clinical outcome.
Aztreonam
Ceftazidime-avibactam
MBLs
OXA-48 like
Journal
Indian journal of medical microbiology
ISSN: 1998-3646
Titre abrégé: Indian J Med Microbiol
Pays: United States
ID NLM: 8700903
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
26
03
2021
accepted:
03
04
2021
pubmed:
25
4
2021
medline:
29
12
2021
entrez:
24
4
2021
Statut:
ppublish
Résumé
Serious infections caused by MBLs with or without OXA-48-like expressing Enterobacterales remain challenging to treat. Since aztreonam is stable to MBLs, it can be combined with ceftazidime/avibactam to protect against concurrently expressed ESBLs and class C β-lactamases in MBL pathogens. However, in the light of dose-limiting hepatotoxicity of aztreonam, short half life of avibactam, significant protein binding of aztreonam, appropriate dosing and method of administration to optimize PK/PD and toxicodynamics for this combination is being debated. Based on in-vitro PK/PD studies, simultaneous administration of 6/1.5 g of ceftazidime/avibactam and 8 g of aztreonam per day has been recently suggested.
Identifiants
pubmed: 33892973
pii: S0255-0857(21)00057-8
doi: 10.1016/j.ijmmb.2021.04.002
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Azabicyclo Compounds
0
Drug Combinations
0
avibactam, ceftazidime drug combination
0
Ceftazidime
9M416Z9QNR
beta-Lactamases
EC 3.5.2.6
Aztreonam
G2B4VE5GH8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
286-288Informations de copyright
Copyright © 2021 Indian Association of Medical Microbiologists. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest None.